RNA Technology Driving the New Wave of Therapeutics

Share this:
Published: 14 Sep 2018

This Drug Discovery TOE depicts trends across RNA technology driving a new wave of therapeutics. Different, stable, non-Immunogenic mRNA therapies, targeted RNAi technologies and therapeutics, CAR T-cell therapy, antisense therapeutics, RNA-based delivery platforms, and DNA-directed RNAi approaches are discussed in the TOE. Clinical trials of HIV vaccines is also depicted. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Targeted RNAi technology, enhanced disease management, non-immunogenic mRNA therapies, antisense therapeutics, RNA therapy, delivery platforms, DNA-directed RNAi approach, CAR T-cell therapy


Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..